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Abstract
Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have 
over 10 years overall survival. Using modern combination therapies – with or without the addition 
of high-dose melphalan and autologous stem cell transplantation – up to 80% of patients reach a 
complete response. As a logical and necessary step forward, clinical studies have explored 
strategies to detect minimal residual disease (MRD) and its correlation with clinical outcomes. In 
this context, MRD has been proposed as a regulatory endpoint for drug approval in newly 
diagnosed multiple myeloma. To better define the role of MRD negativity in relation to clinical 
outcomes, we undertook a meta-analysis including published clinical trials of newly diagnosed 
multiple myeloma patients. We applied a random effects model which weighted studies using the 
inverse-variance method. Studies were combined on the scale of the logarithm of the hazard ratio 
(HR) and the corresponding standard error. We found that remaining MRD positive was associated 
with worse progression-free survival (HR=2.85; 95% confidence interval (CI) 2.17–3.74; P<0.001) 
and overall survival (HR=2.08; 95% CI 1.44–3.01; P<0.001). Our results show that MRD 
negativity is a strong predictor of clinical outcomes, supportive of MRD becoming a regulatory 
endpoint for drug approval in newly diagnosed multiple myeloma.
INTRODUCTION
At the start of the 21st Century, in the U.S., multiple myeloma had an average overall 
survival of about 3 years.1 Driven by access to better drugs, younger patients (<50 years) 
showed more than 10 years median overall survival by 2014.1 The U.S. Food and Drug 
Administration (FDA) approved 14 new drugs in the treatment of cancer in 2015; four of 
these were approved for the treatment of multiple myeloma (panobinostat, daratumumab, 
elotuzumab, and ixazomib).2 In 2015 and 2016, expanded label indications were FDA 
approved for lenalidomide and carfilzomib, respectively.2
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A few years ago, using older drugs followed by high-dose melphalan (HDM) and autologous 
stem cell transplantation (ASCT), only a smaller fraction of patients obtained a complete 
response (CR).3 Today, using modern combination therapies, with or without the addition of 
HDM-ASCT, 100% of patients achieve a treatment response (overall response) with up to 
80% of these patients reaching a CR.3 As a necessary and logical step forward, clinical 
studies have explored strategies to detect minimal residual disease (MRD) and its correlation 
with clinical outcomes. Both progression-free survival and overall survival have been 
associated with MRD in several studies3, suggesting that MRD negativity is a predictor of 
better clinical outcomes in multiple myeloma.4
Although individual smaller studies have suggested that MRD is associated with clinical 
outcomes3, to provide formal scientific evidence, we undertook a meta-analysis including 
published clinical trials of newly diagnosed multiple myeloma patients.
PATIENTS AND METHODS
On December 22, 2015, we conducted a systematic search for clinical trials of newly 
diagnosed multiple myeloma patients with information on MRD and clinical outcomes. We 
applied the following MEDLINE (via PubMed), EMBASE, and Cochrane’s Central Register 
of Controlled Trials (CENTRAL) search strategy: ((((Clinical trial[ptyp] OR random*[ti] 
OR (blinded OR blind) OR “randomized controlled trial” [tiab] OR rct[ti] OR “clinical trial”
[ti] OR trial*[ti]))) AND (Flow cytometry[mh] OR flow[tiab] OR flow 
microfluoromet*[tiab] OR polymerase chain reaction[mh] OR pcr[tiab] OR “polymerase 
chain reaction”[tiab] OR gene expression profiling[mh] OR molecular[tw] OR sequence 
analysis[mh] OR “sequence analysis”[tiab] OR sequenc*[tiab] OR “minimal residual 
disease”[tiab] OR mrd[tiab])) AND (multiple myeloma[mh] OR “multiple myeloma”[ti] OR 
“plasma cell myeloma*”[ti]). Taking this approach, a total of 390 potential studies were first 
identified; however, after careful review of each individual abstract, we excluded 370 since 
they were not clinical trials with MRD assessment in multiple myeloma. Thus, 20 studies 
clinical trials of newly diagnosed multiple myeloma patients with information on MRD and 
clinical outcomes were identified and assessed for inclusion in this meta-analysis (Figure 1). 
Since all the 20 published studies did not include all details required for our pre-planned 
statistical analysis, we contacted the corresponding authors to obtain hazard ratio (HR) 
estimates and corresponding confidence intervals (CI) for the association between MRD and 
clinical outcomes.
Statistical analysis
Four manuscripts were included in the meta-analysis for progression-free survival and two 
were included for overall survival. Each paper used a different landmark time point for MRD 
evaluation; these included: after eight cycles of therapy5, after six cycles of therapy6, at 100 
days post-ASCT7, and 3–6 months post-ASCT8. Two patients in the original Korde et al.5 
analysis were removed from the hazard ratio calculation due to either not having sufficient 
follow-up or progressing prior to the landmark time. In Silvennoinen et al.8, only patients 
achieving a CR or a near-(n)-CR were included in the HR calculation; for the other included 
studies, all patients were included. The meta-analysis was conducted using a random effects 
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model, which weighted studies using the inverse-variance method. Studies were combined 
on the scale of the logarithm of the hazard ratio and the corresponding standard error. The 
analysis used the package ‘metafor’ in R Statistical Platform, v 3.2.3.9, 10
RESULTS
Upon careful review of the 20 identified studies5–8, 11–26, 4 studies were excluded because 
they reported on allogeneic transplantation11–14; 7 were excluded because they did not 
evaluate the association between MRD status and progression-free survival and/or overall 
survival15–21; 4 were excluded because they analyzed overlapping cohorts of patients 
(duplicates)22–25; and 1 was excluded because the timing of MRD analysis was not 
specified26 (Figure 1). Four studies with information on MRD status and HR for 
progression-free survival were included in the final analysis5–8; three studies had 
information on overall survival5–7 (however, one study had no deaths during the original 
follow-up window5) so two studies provided hazards ratios for overall survival.
Among the four studies included in the main analysis5–8, three used multiparameter flow-
cytometry5–7 and one study used allele-specific quantitative polymerase chain reaction8, 
both with a sensitivity of at least 1 in 10,000 cells (10−4) to determine MRD status.3 In line 
with standard methodology9, 10, the random effects model weighted studies based on the 
inverse-variance method; the largest study (Paiva et al.)7 had the largest weight (W random = 
60.4%) in the meta-analysis; and the smallest study (Korde et al.)5 had the smallest weight 
(W random = 2.2%) (Figure 2). Despite inherent differences across included studies (e.g., 
including eligibility criteria, use of drugs, application of MRD assays), all HRs were in the 
same direction favouring MRD negativity for a longer progression-free survival. Overall, the 
meta-analysis show that, compared to who achieved MRD negativity, patients who remained 
MRD positive had worse progression-free survival (HR=2.85; 95% CI 2.17–3.74; P<0.001) 
(Figure 2).
In addition to investigating MRD status in relation to progression-free survival, we were also 
interested in assessing the association between MRD negativity and overall survival. As 
described above, 4 studies with information on MRD status and hazards ratios for 
progression-free survival were included in the final analysis and 3 of these had information 
on overall survival5–7. However, due to the use of modern effective combination therapy, the 
study by Korde et al. had no deaths during the original follow-up window (up to 30 
months).5 Therefore, the studies by Paiva et al. and Mateos at al. were the only two that 
provided hazards ratios for overall survival.6, 7 Based on these two studies, our meta-analysis 
showed that remaining MRD positive was associated with a higher risk of death (HR=2.08; 
95% CI 1.44–3.01; P<0.001) (Figure 2).
CONCLUSIONS
For several decades, only limited progress was made in the field of drug development for 
multiple myeloma. Driven by access to new effective drugs, in 2016, newly diagnosed 
multiple myeloma patients – on average – have over 10 years overall survival in the U.S.3 
Using modern combination therapies – with or without the addition of high-dose melphalan 
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and autologous stem cell transplantation – up to 80% of patients reach a complete response.3 
Consequently, clinical studies have explored strategies to detect MRD and its correlation 
with clinical outcomes. Furthermore, in this context, MRD has been proposed as a 
regulatory endpoint for drug approval in newly diagnosed multiple myeloma.27, 28 To fill 
important gaps in the literature, we were motivated to conduct a meta-analysis including all 
published clinical trials of newly diagnosed multiple myeloma patients. Using a robust 
random effects model, we found that MRD positivity is associated with worse progression-
free survival (HR=2.85; P<0.001) and overall survival (HR=2.08; P<0.001). Our results are 
very important as they provide formal scientific evidence to the fact that MRD negativity is 
associated with better clinical outcomes in newly diagnosed multiple myeloma.
Although stringent criteria were applied to identify and include studies for our meta-
analysis, inherently, similar to any meta-analysis, there were some differences between the 
included studies. For example, the studies by Paiva et al. and7 Silvennoinen et al.8 used 
various combinations including bortezomib and dexamethasone (with or without alkylating 
drugs) followed by high-dose melphalan and autologous stem cell transplantation, while the 
study by Mateos et al.6 used combinations including bortezomib and prednisone followed by 
maintenance therapy with either bortezomib/thalidomide or bortezomib/prednisone for up to 
3 years.6 Given that there are differences in access to myeloma drugs across regions – and, 
indeed, these three studies were all conducted in Europe – it seems reasonable to conclude 
that these regimens are quite applicable to European treatment traditions. As illustrated in 
Figure 2, these three studies consistently showed that MRD positivity was associated with an 
HR between 2.5 and 3.5 (Figure 2). As a consequence of the rapid access to better myeloma 
drugs in the U.S. the myeloma treatment field has been moving fast forward and new 
combination therapies have been developed.2 The study by Korde et al.5 was a single arm 
phase 2 study open for newly diagnosed multiple myeloma patients of all ages (18 years and 
older). Per protocol, all patients received 8 cycles of carfilzomib, lenalidomide, and 
dexamethasone (CRd) combination therapy, followed by 2 years of lenalidomide 
maintenance therapy; and none of the enrolled patients underwent upfront high-dose 
melphalan and autologous stem cell transplantation; however, on a separate protocol, 
younger and older fit patients were offered stem cell collection for potential future use (i.e. 
delayed high-dose melphalan and autologous stem cell transplantation). Based on available 
literature, CRd combination therapy has the highest and deepest response rate for multiple 
myeloma patients to date5, 29, and, consequently, in the study by Korde et al.5 MRD 
negativity was associated with an HR of 10.4 (Figure 2). Per standard conventions9, 10, in 
our meta-analysis, the random effects model weighted studies based on the inverse-variance 
method, and, thus, the largest study (Paiva et al.)7 had the largest weight on the HR in the 
meta-analysis while and the smallest study (Korde et al.)5 had the smallest weight. It should 
be emphasized that although there are inherent differences across clinical trials, all HRs for 
the included studies were in the same direction favouring MRD negativity for a longer 
progression-free survival as well as overall survival.
Other aspects of difference across included studies include the actual MRD assays and the 
timing for MRD testing. As discussed above, among the four studies included in the main 
analysis5–8, three used multiparameter flow-cytometry5–7 and one study used allele-specific 
quantitative polymerase chain reaction8, both with a sensitivity of at least 1 in 10,000 cells 
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(10−4) to determine MRD status.3 To harmonize procedures and to ensure that MRD status 
has the same meaning across studies, the International Myeloma Working Group (IMWG) 
recently revised the response criteria for myeloma and included MRD negativity as the 
highest degree of response to treatment30. Based on the 2016 IMWG criteria, MRD 
negativity can be defined by either multiparameter flow-cytometry-based or molecular-based 
assays; and MRD status shall only be determined in patients who have achieved a 
conventional CR30.
Moving forward, as better and better drugs become available for the treatment of multiple 
myeloma, ironically, traditional regulatory endpoints (i.e. overall survival and progression-
free survival) will become key barriers for drug development. In fact, future registrational 
clinical trials will require very large sample sizes and very long followup (to be able to 
provide sufficient statistical power) to show that new drugs have an overall survival and/or 
progression-free survival benefit. Thus, due to these inherent limitations of traditional 
regulatory endpoints, future myeloma drugs will become majorly delayed and costs for drug 
development will increase significantly. Clearly, there is an urgent need for reliable surrogate 
regulatory endpoints for drug approval.27, 28 Indeed, Gormley et al, from the FDA, recently 
published a paper on regulatory perspectives on MRD testing in multiple myeloma.4 In their 
paper, the authors conclude that MRD assessment in multiple myeloma has the potential to 
become a surrogate clinical endpoint that could be used to support regulatory purposes for 
drug review.4 As pointed out by Gormley et al., standardization of MRD testing and 
consensus within the multiple myeloma community as to the role of MRD and possible 
incorporation into the response criteria will be integral steps towards this end.4 The 
International Myeloma Working Group (IMWG) has worked extensively to revise the 
response criteria for multiple myeloma and an updated version of the IMWG response 
criteria which will include guidelines for MRD testing is anticipated to be published in 2016. 
Also, concerted efforts aiming to standardize MRD testing and consensus within the 
multiple myeloma community are ongoing. The FDA has emphasized the importance of 
future meetings to facilitate a consensus process in the U.S. and expressed their interest in 
reviewing both testing protocols of MRD assays and clinical protocols incorporating MRD.4 
In this context, the results from our meta-analysis play an important role as they provide 
scientific evidence on the impact of MRD negativity as a strong predictor of longer 
progression-free survival and overall survival in newly diagnosed multiple myeloma.
Based on the results from our meta-analysis, we conclude that MRD negativity is associated 
with better progression-free survival and overall survival in newly diagnosed multiple 
myeloma. Our findings are supportive of MRD assessment becoming a surrogate clinical 
endpoint that could be used to support regulatory purposes for drug review in multiple 
myeloma.4 In addition to the results from this meta-analysis; prospective clinical studies are 
ongoing and will to further confirm and expand on our findings.
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FIGURE 1. SEARCH CRITERIA FOR SYSTEMATIC REVIEW
Footnote: On December 22, 2015; we applied a comprehensive MEDLINE (via PubMed), 
EMBASE, and Cochrane’s Central Register of Controlled Trials (CENTRAL) search 
strategy. For details see Methods Section. Upon careful review of the 20 identified 
studies5–8, 11–26, 4 studies were excluded because they reported on allogeneic 
transplantation11–14; 7 were excluded because they did not evaluate the association between 
MRD status and progression-free survival and/or overall survival15–21; 4 were excluded 
because they analyzed the same cohort of patients (duplicates)22–25; and 1 was excluded 
because the timing of MRD analysis was not specified26.
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FIGURE 2. MRD STATUS AND CLINICAL OUTCOMES IN NEWLY DIAGNOSED 
MULTIPLE MYELOMA
*A higher hazard ratio indicates increased risk for each survival endpoint.
Footnote: Four studies with information on MRD status and hazards ratios for progression-
free survival were included in the final analysis5–8; three studies had information on overall 
survival5–7 (however, one study had no deaths during the original follow-up window5) so 
two studies provided hazards ratios for overall survival.
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